Male Factor Infertility in India: Causes, Tests & Treatment

• Male factor contributes to about 40-50% of Indian fertility issues, so a semen analysis should be a first-line test for both partners, not an afterthought.
• A semen analysis (Rs 500-2,000 at NABL labs) is the single most useful first test; one abnormal result should always be repeated after 2-4 weeks before any conclusion.
• Many causes are reversible: varicocele, hormone problems, thyroid issues, and lifestyle factors like weight, smoking, heat and testosterone use often improve over 3-6 months.
• Even azoospermia (no sperm in the ejaculate) is rarely the end of the road: surgical sperm retrieval plus ICSI helps a large share of men become biological fathers.
• Treatment matches severity, from lifestyle changes and IUI for mild cases to IVF-ICSI and micro-TESE for severe cases, and donor sperm or adoption as parallel paths.

Across Indian fertility-clinic data reported by ISAR (Indian Society for Assisted Reproduction) and FOGSI, male factor contributes to roughly 40 to 50 percent of all fertility difficulty, comparable to global figures. A rough breakdown looks like this: pure male factor in about 25-30 percent of couples, pure female factor in about 30-35 percent, combined factors in 15-20 percent, and unexplained infertility in the remaining 15-20 percent.

The practical message is simple. In any couple struggling to conceive, the chance that the male partner is contributing is roughly equal to the chance the female partner is. The common cultural assumption that fertility is a "woman's problem" is not supported by the data, and acting on that assumption wastes time, money, and emotional energy.

That is why a semen analysis belongs at the very start of the workup, alongside the female partner's fertility tests. Too often, women undergo hormonal panels, ultrasounds, tubal tests, and even laparoscopy before their partner has had a basic semen test. ISAR and FOGSI both advocate for routine, early semen analysis to avoid exactly this.

Some India-specific patterns are worth noting. Severe low counts and azoospermia (no sperm in the ejaculate) appear somewhat more often in certain Indian sub-populations, likely reflecting a mix of environmental and occupational exposures, varicocele, past genital tuberculosis, and genetic factors. Globally, average sperm counts have also declined over recent decades, with mechanisms still debated and likely including obesity, diet, and environmental factors. Male fertility declines with age too, more gradually than female fertility, with rising DNA damage and slower conception from the mid-40s even when the partner's age is held constant.

A semen analysis is the single most important first test in male fertility evaluation. At NABL-accredited Indian labs (SRL, Metropolis, Thyrocare, and most hospital labs) it costs roughly Rs 500 to 2,000, with results in 24 to 48 hours. It is the foundation that shapes every later decision, and our guide to the sperm analysis test in India walks through booking and reading it in detail.

The test scores several parameters against World Health Organization reference values. The 2010 (5th edition) thresholds are still widely used in Indian practice, with an updated 6th edition published in 2021. The main values to recognise are below.

How the sample is collected strongly affects the result, so getting this right avoids a falsely alarming report. The standard preparation is 2 to 7 days of abstinence, collection by masturbation into the lab's sterile container, capturing the entire ejaculate, and delivering it to the lab within 30 to 60 minutes if collected at home. Many men prefer to use a private room at the lab to avoid transport delay.

Common mistakes that distort results include the wrong abstinence period, using lubricants (most reduce motility), losing the first portion of the ejaculate (which carries the most sperm), contamination, and heat or cold during transport. Any of these can make a normal sample look abnormal.

Two facts make repeat testing essential. First, semen quality varies a lot from sample to sample in the same man. Second, sperm take about 72 to 74 days to mature, so a recent illness, fever, or stressful period can show up months later, and improvements from lifestyle changes also take a few months to appear. For these reasons, a single abnormal result should be confirmed with a second sample at least 2 to 4 weeks later before drawing firm conclusions.

Specialised andrology labs may add sperm DNA fragmentation (DFI), oxidative-stress markers, or sperm-function tests, usually adding Rs 2,000 to 8,000. These are reserved for specific situations such as repeated IVF failure or recurrent miscarriage. Finally, context matters: normal results do not guarantee fertility, and mildly abnormal results do not rule out natural conception. The semen analysis is a starting point, not a verdict. For the terminology on your report, our fertility abbreviations explainer is a handy companion.

Male factor infertility is not one condition but several, each with different causes and treatments. Naming the category guides the next step.

Low count (oligozoospermia) is the most common abnormality. Causes include varicocele (dilated scrotal veins, found in about 15 percent of all men and 35 percent of infertile men), hormone disorders, infections, gonadotoxic treatments such as chemotherapy or pelvic radiation, anabolic steroid or testosterone use, environmental toxins, occupational heat, severe obesity, certain genetic conditions, and idiopathic cases (no cause found).

Low motility (asthenozoospermia) shares many of these causes and often appears alongside low count. It can also reflect sperm DNA damage from oxidative stress, structural sperm defects, anti-sperm antibodies, or infection. Abnormal shape (teratozoospermia) likewise travels with the other two.

Azoospermia (no sperm in the ejaculate) affects about 1 percent of men and 10-15 percent of infertile men, and splitting it into two types is critical:

A varicocele is a dilation of the veins draining the testis, and it is the single most common identifiable and treatable cause of male factor infertility, present in about 15 percent of all men and 35 percent of men with fertility difficulty. It happens when valves in the spermatic veins leak, allowing blood to pool. The left side is affected more often than the right because of how the veins drain.

Most varicoceles cause no symptoms and are found during fertility evaluation; some cause a dull scrotal ache, especially after standing or exercise. The likely reason they harm fertility is heat: sperm production needs a temperature 2 to 3 degrees Celsius below body temperature, and pooled blood warms the testis and adds oxidative stress, raising DNA fragmentation and lowering motility.

Diagnosis is by examination (ideally standing, with a Valsalva strain) and confirmed with a scrotal Doppler ultrasound. Varicoceles are graded 1 to 3, plus "subclinical" (only seen on imaging). Treatment, when indicated, is usually microsurgical varicocelectomy through a sub-inguinal approach, the gold standard with the lowest recurrence (under 5 percent), done as a day-care procedure. Percutaneous embolisation is an alternative.

Repair is generally offered when the varicocele is palpable (not subclinical), semen parameters are abnormal, the female workup is normal or correctable, and the couple has been trying for at least a year. Outcomes are encouraging: roughly 60 to 70 percent of men see improved semen parameters, natural pregnancy rates improve, and DNA fragmentation usually falls, with maximum benefit at 3 to 6 months. It is fair to set expectations that improvement is not guaranteed and may not be enough for natural conception in every case. In India, microsurgical varicocelectomy is widely available with outcomes comparable to international centres, typically costing Rs 30,000 to Rs 1.5 lakh depending on approach, city, and hospital tier.

Hormone problems cause a meaningful minority of male factor cases and are often very treatable once identified. A hormonal workup in men with abnormal semen usually includes morning FSH, LH, total testosterone, prolactin, and a thyroid panel, sometimes with oestradiol and others.

Hypogonadotropic hypogonadism means low LH and FSH with low testosterone, from a pituitary or hypothalamic problem. It is one of the most treatable causes: injections of hCG, often with FSH, can restore sperm production over 3 to 12 months. High prolactin suppresses the same hormones and is usually corrected with dopamine-agonist tablets (cabergoline or bromocriptine); our explainer on high prolactin covers this in depth. Both thyroid extremes can also lower fertility, which is why a thyroid check is routine; see thyroid and fertility for the full picture.

Primary testicular failure shows the opposite hormonal pattern, high FSH and LH with low testosterone, meaning the testes are not responding. Causes include Klinefelter syndrome (47,XXY, the most common chromosomal cause of male infertility), Y-chromosome microdeletions, past chemotherapy or radiation, and severe varicocele. Genetic testing (karyotype and Y-microdeletion analysis) is recommended in severe oligozoospermia and azoospermia.

One reversible cause deserves emphasis: testosterone supplementation. Testosterone gels, injections, or tablets switch off the body's own signals to the testes, and sperm counts typically fall to zero within 3 to 6 months. Recovery after stopping takes 6 to 18 months and is not always complete. Any man using or considering testosterone who may want children should have a fertility discussion first and consider banking sperm before starting.

Lifestyle is where men have the most direct control, and many mild-to-moderate cases improve over 3 to 6 months with focused changes alone. The interventions below are listed roughly in order of impact, the biggest first.

Antioxidant supplements, formulations with zinc, selenium, vitamins C and E, coenzyme Q10, L-carnitine and folate, are heavily marketed for male fertility. The honest picture is mixed. Some studies show modest improvements in semen parameters, particularly in men with high oxidative stress, but a well-conducted randomised trial in couples with unexplained infertility found no improvement in pregnancy rates from antioxidants. They are most reasonable in men with measured oxidative stress or abnormal parameters, not as a guaranteed fix. Common male-fertility multivitamins in Indian pharmacies run about Rs 500 to 2,000 a month.

Keep perspective on the everyday worries too. Mobile phones, tight clothing, and similar low-dose exposures have weak or contradictory evidence. The interventions that actually move the needle are weight, smoking, alcohol, heat, and treating any identified hormonal or anatomical cause. If your main goal is simply boosting semen volume and quality, our practical guide on how to produce more semen separates the evidence from the hype.

Treatment depends on the cause, severity, the female partner's situation, both partners' ages, and personal preferences. The aim is to match the lightest effective treatment to the problem, and to re-test after about 3 to 6 months of any optimisation since that is one full sperm-production cycle. Deciding between options is easier with our IUI vs IVF decision guide.

Severe male factor, especially counts under 5 million per mL and azoospermia, carries a higher chance of a genetic or structural cause. Identifying these guides treatment and counselling about future children.

Klinefelter syndrome (47,XXY) is the most common chromosomal cause, affecting about 1 in 600 men, and is often first found during a fertility workup. Encouragingly, micro-TESE recovers sperm in about 40-60 percent of cases, best done before any testosterone replacement, which suppresses residual sperm. Y-chromosome microdeletions in the AZF region matter by location: AZFa or complete AZFb deletions usually mean no recoverable sperm, while AZFc deletions often allow retrieval, but are passed to all sons. Karyotype testing also catches balanced translocations, which can cause low counts and recurrent pregnancy loss in the partner.

Congenital absence of the vas deferens (CBAVD) is an obstructive cause in which about 80 percent of men carry a CFTR (cystic fibrosis) gene change. Testing both partners before ICSI is important: if both carry CFTR changes, embryos can be screened with PGT to prevent cystic fibrosis. For couples, this sits within wider carrier screening (such as thalassaemia, which is especially relevant in India).

Structural and India-specific causes round out the picture: vas or ejaculatory-duct blockage, retrograde ejaculation (semen entering the bladder, common in diabetes and after some surgeries), and past genital tuberculosis, which can block the male ducts (and the female tubes) and is more common against India's higher background TB exposure. Where suspected, history, examination, and targeted testing help confirm it. Genetic counselling is increasingly part of comprehensive male-factor care before assisted reproduction.

The biology is universal, but the social context in India shapes how male factor is diagnosed and discussed. Pressure to conceive after marriage is usually directed at the woman first, so male evaluation is often delayed and women may undergo extensive testing before their partner has a simple semen analysis. Naming the real diagnosis clearly can help reframe family understanding and stop unnecessary interventions on a partner with a normal workup.

Stigma is real. Cultural links between male fertility, masculinity, and family lineage can make a male factor finding especially hard, and some men avoid testing out of fear of the result. Compassionate communication, involving both partners throughout, and access to counselling all matter. Many couples also choose not to disclose the specific cause even to close family, which is a valid choice but can cut them off from support, so it helps to decide together what to share and with whom.

Assisted reproduction and donor sperm raise their own questions in many Indian families, and the ART Act 2021 governs donor use with strict screening and consent rules. Practical access varies too: large metros have dedicated andrology and reproductive-urology services, while smaller cities may require travel for procedures like micro-TESE. Costs for male evaluation are modest until ICSI is needed, after which they converge with general IVF costs. Through all of this, the couple is a team. The female partner may feel over-medicalised, the male partner may feel guilt or shame, and working through it together, with professional support when needed, protects the relationship. Our guides on explaining TTC to your partner can help.

Fertility is a couple's journey, and the male partner should be assessed early rather than last. See a doctor (a gynaecologist, urologist, or andrologist) in these situations:

The outlook for male factor infertility has transformed over the past three decades. Forms once considered untreatable can now lead to biological parenthood for many couples.

Mild male factor often responds to lifestyle changes, treating any cause, and a few months of trying naturally, with IUI as a next step if needed. Moderate male factor frequently calls for IVF or ICSI. Severe male factor is treated with IVF-ICSI, where success depends mostly on the female partner's age once fertilisation is achieved. Azoospermia outcomes vary by type: obstructive azoospermia has an excellent outlook with simple retrieval and ICSI, while non-obstructive azoospermia has roughly 40-60 percent sperm recovery with micro-TESE.

Where biological fatherhood through a man's own sperm is not possible, donor sperm and adoption in India are meaningful parallel paths, the latter regulated by the CARA framework. If you have had a child before and are now struggling, secondary infertility deserves the same full evaluation, including a semen analysis. The overall message is steady and hopeful: with accurate diagnosis, an individualised plan, realistic expectations, and emotional support, most men with male factor infertility can become fathers.

• WHO laboratory manual for the examination and processing of human semen (6th edition)
• WHO: Infertility fact sheet
• American Urological Association / ASRM: Diagnosis and Treatment of Infertility in Men (clinical guideline)
• American Society for Reproductive Medicine: Diagnostic evaluation of the infertile male
• NHS: Infertility - Causes
• ICMR National Guidelines for Accreditation, Supervision and Regulation of ART Clinics in India